Generare key facts
as of Oct 2026- Operator of a biotechnology company intended to discover novel drug leads of microbial origins.
- Generare is valued at approximately $12.1M as of Oct 2026 (last reported valuation).
- It has raised $28.6M; the latest was Early Stage VC ($23.1M) in Apr 2026.
- Notable investors include La French Tech, Agoranov, Super Capital, Better Angle, Daphni — 11 tracked in total.
- Status: Privately Held (backing).
Generare's last reported valuation, Oct 2024. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Generare: the Monday email on marks, rounds and moves
Generare funding rounds
No funding rounds for Generare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Generare
11+Membership and data by Private Market View
Generare valuation
Generare's last reported valuation was $12.1 million in Oct 2024. No priced round, secondary trade or fund mark has surfaced since.
Generare investors
11 investors are on record for Generare, including La French Tech, Agoranov, Super Capital and Better Angle. By type, the record holds 5 venture capital firms and 1 hedge fund.
About Generare
Operator of a biotechnology company intended to discover novel drug leads of microbial origins. The company has developed a comprehensive map of the biosynthetic landscape and uses experimental data to predict which genes could yield valuable new molecules, enabling pharmaceutical companies and research institutions to access molecules that offer novel modes of action for drug development.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2022
- Employees
- 33
- Website
- generare.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.